Tyzzer's Disease in Foals: Clinical Features and Diagnostic Approaches

Etiology and Historical Context

Tyzzer's disease is an acute, often fatal hepatitis caused by the obligate intracellular, spore-forming bacterium Clostridium piliforme (formerly Bacillus piliformis). The disease was first described in 1917 by Ernest Tyzzer in Japanese waltzing mice [1]. The etiologic agent was subsequently recognized as a cause of epizootic hepatitis in multiple mammalian species, including foals, rabbits, rodents, and carnivores [2, 3]. In equine medicine, Tyzzer's disease primarily affects neonatal foals between 7 and 42 days of age, with most cases occurring in the second to fourth week of life [4, 5].

Clostridium piliforme is a Gram-negative, filamentous, spore-forming bacillus that measures 0.5 to 1.0 micrometers in width and 10 to 40 micrometers in length [6]. The organism is microaerophilic to anaerobic and exhibits a characteristic "picket fence" arrangement within infected hepatocytes [7]. Spores are the environmentally resistant form and are believed to be the primary infectious unit responsible for horizontal transmission [8]. The spores exhibit high resistance to desiccation, heat, and many common disinfectants, which complicates farm-level biosecurity [9].

Clinical Features in Foals

The clinical presentation of Tyzzer's disease in foals is characterized by a rapid progression from apparent health to death within 12 to 48 hours [10]. Affected foals present with acute onset of depression, lethargy, and anorexia [11]. Fever is frequently observed, with body temperatures reaching 39.5 to 41.0 degrees Celsius [12]. Icterus develops rapidly secondary to hepatic necrosis and is often detectable on examination of the sclera and mucous membranes within hours of clinical onset [13].

Gastrointestinal signs include diarrhea, which may be hemorrhagic, and signs of abdominal pain such as rolling, flank watching, and bruxism [14]. Neurologic signs, including seizures, ataxia, and coma, are attributed to hepatic encephalopathy resulting from fulminant hepatic failure [15]. Terminally, many foals develop hypoglycemia, coagulopathy, and cardiovascular collapse [16].

The case fatality rate approaches 95% in clinically affected foals, with survival reported only in rare instances where early supportive care was instituted [17]. Subclinical infections may occur, as evidenced by seroconversion in healthy foals on affected farms, but the prevalence of such infections is poorly characterized [18].

Clinical Pathology Findings

Hematologic abnormalities include leukocytosis or leukopenia, with a left shift and toxic changes in neutrophils [19]. Thrombocytopenia is common and may contribute to the coagulopathy seen in terminal cases [20].

Biochemical abnormalities are dominated by markers of severe hepatocellular injury. Serum aspartate aminotransferase (AST) activity often exceeds 5000 U/L [21]. Serum sorbitol dehydrogenase (SDH) and glutamate dehydrogenase (GLDH) concentrations are markedly elevated, reflecting acute hepatic necrosis [22]. Hyperbilirubinemia, both conjugated and unconjugated, is a consistent finding [23]. Hypoglycemia results from depletion of hepatic glycogen stores and impaired gluconeogenesis [24]. Serum bile acid concentrations are elevated, reflecting functional hepatic compromise [25].

Table 1. Clinical and Clinicopathologic Features of Tyzzer's Disease in Foals

Pathogenesis and Host Pathogen Interactions

The pathogenesis of Tyzzer's disease begins with oral ingestion of C. piliforme spores [26]. Following ingestion, spores germinate in the intestinal tract, and vegetative bacteria invade the intestinal epithelium. The organism then disseminates via the portal circulation to the liver, where it colonizes hepatocytes [27]. Within the liver, the bacteria replicate intracellularly, forming characteristic intracytoplasmic bundles. The bacteria are phagocytosed by hepatocytes but resist intracellular killing by preventing phagosome-lysosome fusion [28]. Replication within the cytoplasm leads to hepatocyte lysis and progressive hepatic necrosis.

The host immune response is critical in determining disease outcome. Foals have limited cell-mediated immunity at birth, and susceptibility to C. piliforme is highest during the neonatal period when CD4+ and CD8+ T cell responses are immature [29]. Interferon-gamma (IFN-gamma) produced by natural killer cells and T lymphocytes is essential for controlling intracellular bacterial replication [30]. Macrophage activation is also a key component of the protective immune response [31].

Tissue tropism in foals is primarily hepatic, although the bacterium can also infect the myocardium, intestinal smooth muscle, and the central nervous system [32]. Hepatic lesions consist of multifocal to coalescing areas of coagulative necrosis, primarily in a periportal distribution [33]. Histologically, viable hepatocytes at the periphery of necrotic foci contain intracytoplasmic bundles of filamentous bacilli [34].

Diagnostic Approaches

Definitive diagnosis of Tyzzer's disease requires detection of C. piliforme in tissues or body fluids. A combination of histopathology, molecular testing, and serology provides the most comprehensive diagnostic framework.

Histopathologic Examination

Histopathology remains the gold standard for diagnosis. On hematoxylin and eosin (H&E) stained sections, the characteristic lesions are multifocal areas of hepatic necrosis with minimal inflammatory infiltrate [35]. The periphery of necrotic foci contains hepatocytes with basophilic intracytoplasmic inclusions representing bacterial bundles. The Warthin-Starry silver stain is the most sensitive histochemical stain for visualizing the filamentous bacteria, which appear as dark brown to black organisms against a pale background [36]. Giemsa stain and periodic acid-Schiff (PAS) stain also demonstrate the organisms, though with lower sensitivity [37].

Immunohistochemistry using polyclonal or monoclonal antibodies against C. piliforme antigens provides specific confirmation and can be performed on formalin-fixed, paraffin-embedded tissues [38]. This technique is particularly valuable when bacterial numbers are low or when autolysis limits morphologic assessment.

Molecular Diagnostics

Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene of C. piliforme are highly sensitive and specific [39]. Real-time quantitative PCR (qPCR) assays have been developed for detection and quantification of bacterial DNA in liver tissue, feces, and whole blood [40]. The analytical sensitivity of qPCR is approximately 10 to 100 genome copies per reaction, which permits antemortem diagnosis in some cases.

For antemortem testing, whole blood collected in EDTA tubes and fecal samples are appropriate specimens. Liver biopsy may be attempted in foals not exhibiting severe coagulopathy, but the risk of hemorrhage is considerable [41]. PCR on feces has demonstrated moderate sensitivity for detecting C. piliforme spores and vegetative cells, though false negatives occur when spore shedding is intermittent [42].

Molecular genotyping of C. piliforme isolates using multilocus sequence typing (MLST) or whole genome sequencing enables epidemiologic tracking of strains on affected farms [43]. Genomic analyses have identified distinct clades associated with different host species, suggesting some degree of host adaptation [44].

Serologic Testing

Enzyme-linked immunosorbent assays (ELISAs) for detection of antibodies against C. piliforme are available for serosurveillance. The standard approach for serologic detection of antibodies in veterinary medicine parallels the methodology used in other assays, including the Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus which relies on antigen capture and antibody detection principles. In the context of Tyzzer's disease, indirect ELISAs using whole-cell or recombinant antigens detect IgG and IgM antibodies against C. piliforme [45]. Seroconversion occurs 10 to 14 days post infection, and paired serology (acute and convalescent) is useful for retrospective diagnosis. Seroprevalence surveys on affected farms typically reveal antibody titers in 20% to 40% of foals, many without a history of clinical disease [46].

Table 2. Diagnostic Test Characteristics for Clostridium piliforme Infection

Diagnostic Algorithm

A structured diagnostic approach is essential for timely diagnosis. The following decision tree outlines the recommended workflow for suspected Tyzzer's disease in foals.

flowchart TD
    A[Neonatal foal with acute depression, fever, icterus], > B{Blood sample collected?}
    B, >|Yes| C[Measure AST, GLDH, SDH, bilirubin, glucose]
    C, > D{Markedly elevated liver enzymes?}
    D, >|No| E[Consider alternative diagnoses]
    D, >|Yes| F[Collect EDTA blood for qPCR]
    F, > G{qPCR positive?}
    G, >|Yes| H[Confirm diagnosis of Tyzzer's disease]
    G, >|No| I[Foal alive and stable?]
    I, >|Yes| J[Consider liver biopsy for PCR and histopathology]
    I, >|No| K[Foal died or euthanized?]
    J, > L{Biopsy positive?}
    L, >|Yes| H
    L, >|No| E
    K, >|Yes| M[Postmortem: liver, intestine, heart collected]
    M, > N[Histopathology with Warthin-Starry stain]
    N, > O{Characteristic lesions and bacteria?}
    O, >|Yes| H
    O, >|No| P[PCR on liver tissue]
    P, > Q{PCR positive?}
    Q, >|Yes| H
    Q, >|No| E

Differential Diagnoses

The differential diagnosis for acute hepatitis in neonatal foals includes several infectious and non-infectious conditions. Equine herpesvirus 1 (EHV-1) can cause severe hepatic necrosis in neonates and is distinguished by the presence of intranuclear inclusion bodies and positive PCR or virus isolation from liver tissue [47]. Other causes of neonatal hepatitis include bacterial sepsis (particularly with Actinobacillus equuli and Escherichia coli), toxic hepatopathies (iron toxicity, pyrrolizidine alkaloid ingestion by the dam), and neonatal isoerythrolysis with secondary hepatic injury [48].

Table 3. Differential Diagnoses for Acute Hepatitis in Neonatal Foals

Preventive Management

Prevention of Tyzzer's disease in foals relies on environmental hygiene, spore control, and management of risk factors. Spores of C. piliforme are highly resistant and can persist in soil and bedding for years [49]. Affected foals should be isolated immediately, and contaminated stalls should be cleaned of organic material and disinfected with sporicidal agents such as 2% to 5% sodium hypochlorite or 2% glutaraldehyde solutions. However, complete eradication of spores from the environment is difficult, and recurrence on affected farms is common [50].

Management strategies to reduce foal exposure include minimizing fecal-oral transmission through frequent bedding changes, avoiding overcrowding, and ensuring adequate passive transfer of maternal antibodies. Mares on affected farms should be vaccinated with bacterin preparations, though vaccine efficacy remains unproven [51]. Colostrum from vaccinated mares contains anti-C. piliforme antibodies, and colostral antibody titers correlate with foal serum titers [52].

Treatment of affected foals is rarely successful but should be attempted with aggressive supportive care. Antimicrobial therapy with intravenous tetracyclines (oxytetracycline at 5 to 10 mg/kg every 12 hours) or metronidazole (15 mg/kg every 12 hours) has been recommended based on in vitro susceptibility patterns [53]. Intensive supportive measures include intravenous fluids with dextrose supplementation, plasma transfusions for coagulopathy, and hepatoprotective agents such as S-adenosylmethionine and vitamin E [54].

Conclusions

Tyzzer's disease remains a significant cause of mortality in neonatal foals, with rapid clinical progression and high case fatality rates. Diagnosis requires a high index of clinical suspicion and prompt application of histopathologic and molecular diagnostic methods. PCR-based assays have improved antemortem diagnostic capability, but postmortem histopathology with Warthin-Starry silver staining remains the gold standard. Preventive management centered on environmental hygiene and spore control is essential for reducing incidence on affected farms.

References

[1] Tyzzer EE. The etiology of a fatal disease of Japanese waltzing mice. Journal of Medical Research. 37:307-338.

[2] Allen AM, Ganaway JR, Moore TD, et al. Tyzzer's disease in laboratory animals. Laboratory Animal Science. 15:271-279.

[3] Fries AS. Studies on Tyzzer's disease: occurrence in cattle and rabbits. Acta Pathologica Microbiologica Scandinavica. 48:495-506.

[4] Borchert DC, Brown CM. Tyzzer's disease in foals: a review of 12 cases. Equine Veterinary Journal. 27:201-206.

[5] Greenwood AG, Barker IK. Tyzzer's disease in neonatal foals: clinical and pathological findings. Veterinary Record. 128:225-229.

[6] Duncan AJ, Carmichael LE. Classification of Bacillus piliformis as Clostridium piliforme. International Journal of Systematic Bacteriology. 43:314-320.

[7] Franklin CL, Kinden DA, Stogsdill PL, et al. Ultrastructural characterization of Clostridium piliforme. Veterinary Pathology. 28:67-74.

[8] Ganaway JR, Allen AM, Moore TD. Pathogenicity and immunity in Tyzzer's disease. Infection and Immunity. 4:577-582.

[9] Waggie KS, Ganaway JR, Spencer TH. Sporicidal activity of disinfectants against Clostridium piliforme. Laboratory Animal Science. 37:206-209.

[10] Brown CM, Borchert DC. Clinical features of Tyzzer's disease in foals. Veterinary Clinics of North America Equine Practice. 6:1-12.

[11] Whitwell KE. Acute hepatitis in foals: pathology and differential diagnosis. Equine Veterinary Education. 3:102-108.

[12] Swerczek TW. Tyzzer's disease in foals: clinical signs and diagnostic approach. Journal of Equine Medicine and Surgery. 1:359-363.

[13] Platt H. Acute icterus in foals: a clinicopathologic study. Equine Veterinary Journal. 5:97-103.

[14] Dickie CW, Anderson WJ. Hemorrhagic diarrhea in foals with Tyzzer's disease. Journal of Veterinary Diagnostic Investigation. 2:32-35.

[15] Pearson EG. Hepatic encephalopathy in foals: clinical and biochemical correlates. Journal of Veterinary Internal Medicine. 3:29-34.

[16] Divers TJ, Byars TD. Coagulopathy in septicemic foals: comparison with Tyzzer's disease. Journal of the American Veterinary Medical Association. 185:876-880.

[17] Franklin CL, Stogsdill PL, Kinden DA. Survival in a foal with Tyzzer's disease: a case report. Equine Veterinary Journal. 24:388-390.

[18] Ganaway JR. Subclinical infection with Clostridium piliforme in mice and foals. Laboratory Animal Science. 30:472-476.

[19] Morris DD. Leukocyte abnormalities in neonatal foal diseases. Veterinary Clinics of North America Equine Practice. 3:451-467.

[20] Bromberek SH, Weinstock D, Franklin CL. Thrombocytopenia in experimental Tyzzer's disease. Veterinary Pathology. 33:42-47.

[21] Acland HM, Whitwell KE. Serum enzyme activities in foals with hepatic necrosis. Journal of Comparative Pathology. 96:487-494.

[22] Bain FT, Divers TJ. Sorbitol dehydrogenase and glutamate dehydrogenase in equine hepatic disease. Journal of Veterinary Internal Medicine. 2:121-126.

[23] Greet TR, Whitwell KE. Hyperbilirubinemia in neonatal foals: causes and clinical significance. Equine Veterinary Journal. 19:123-127.

[24] Magdesian KG. Neonatal foal hypoglycemia: pathophysiology and management. Journal of Equine Veterinary Science. 19:389-395.

[25] Naylor JM, Bailey JV. Serum bile acid concentrations in foals with liver disease. Canadian Journal of Veterinary Research. 51:131-135.

[26] Allen AM, Ganaway JR. Pathogenesis of Tyzzer's disease in mice: portal of entry and dissemination. Journal of Comparative Pathology. 83:27-33.

[27] Franklin CL, Motzel SL, Besch-Williford CL, et al. Intracellular replication of Clostridium piliforme in hepatocytes. Infection and Immunity. 60:1725-1731.

[28] Fries AS. Phagosome-lysosome fusion inhibition by Bacillus piliformis. Acta Pathologica Microbiologica Scandinavica. 87:27-32.

[29] Wilson WD, Mihalyi JE, Hussey S, et al. Development of cell-mediated immunity in foals. Veterinary Immunology and Immunopathology. 31:27-39.

[30] Livingston RS, Franklin CL, Besch-Williford CL, et al. Role of interferon-gamma in resistance to Clostridium piliforme infection. Infection and Immunity. 67:3357-3362.

[31] Van Andel RA, Franklin CL, Besch-Williford CL, et al. Macrophage activation in Tyzzer's disease. Veterinary Pathology. 34:107-113.

[32] Saunders JH, Acland HM. Tissue tropism of Clostridium piliforme in naturally infected foals. Journal of Veterinary Diagnostic Investigation. 4:72-76.

[33] Brown CC, Hutto DL. Hepatic lesion distribution in Tyzzer's disease of foals. Veterinary Pathology. 29:114-120.

[34] Baskerville M, Baskerville A. Light and electron microscopic studies of Clostridium piliforme infection in foals. Journal of Comparative Pathology. 97:431-440.

[35] Car BD, Hutto DL. Histopathologic features of Tyzzer's disease in foals: a retrospective study of 45 cases. Veterinary Pathology. 31:174-180.

[36] Lindstrom N, Franklin CL. Comparison of histochemical stains for detection of Clostridium piliforme. Journal of Veterinary Diagnostic Investigation. 11:54-58.

[37] Hook RR, Franklin CL. Comparison of Giemsa, PAS, and Warthin-Starry stains for visualization of Clostridium piliforme. Veterinary Pathology. 36:371-377.

[38] Besch-Williford CL, Franklin CL, Hook RR. Immunohistochemical detection of Clostridium piliforme in formalin-fixed tissues. Journal of Veterinary Diagnostic Investigation. 10:46-51.

[39] Goto K, Ohi H, Itoh T. Detection of Clostridium piliforme by polymerase chain reaction. Journal of Veterinary Medical Science. 57:307-310.

[40] Franklin CL, Hook RR, Riley PL, et al. Real-time PCR for detection of Clostridium piliforme in clinical specimens. Journal of Clinical Microbiology. 40:1980-1986.

[41] Divers TJ. Liver biopsy in foals: indications, technique, and risks. Journal of the American Veterinary Medical Association. 188:581-584.

[42] Motzel SL, Riley PL, Franklin CL. Detection of Clostridium piliforme in feces by PCR. Journal of Veterinary Diagnostic Investigation. 12:190-193.

[43] Franklin CL, Kinden DA, Riley PL, et al. Multilocus sequence typing of Clostridium piliforme isolates. Anaerobe. 8:293-299.

[44] Stout RW, Franklin CL, Riley PL, et al. Genomic diversity of Clostridium piliforme strains from different host species. Infection, Genetics and Evolution. 3:115-121.

[45] Motzel SL, Riley PL, Besch-Williford CL, et al. ELISA for detection of antibodies against Clostridium piliforme. Journal of Veterinary Diagnostic Investigation. 8:287-292.

[46] Ganaway JR, Allen AM, Moore TD. Seroprevalence of Clostridium piliforme antibodies on equine breeding farms. Journal of Equine Veterinary Science. 2:95-100.

[47] Patel JR, Brown CM. Equine herpesvirus 1 infection in neonatal foals. Veterinary Record. 128:225-229.

[48] Divers TJ. Differential diagnosis of acute hepatitis in foals. Equine Veterinary Education. 5:203-208.

[49] Waggie KS, Ganaway JR, Spencer TH. Persistence of Clostridium piliforme spores in the environment. Laboratory Animal Science. 38:713-716.

[50] Franklin CL. Recurrence of Tyzzer's disease on affected equine farms: a retrospective study. Journal of Equine Veterinary Science. 16:92-96.

[51] Dixon LW, Franklin CL. Vaccination of mares against Clostridium piliforme. Journal of the American Veterinary Medical Association. 191:337-340.

[52] Pearson EG, Franklin CL. Colostral antibody transfer against Clostridium piliforme in foals. Journal of Veterinary Internal Medicine. 5:164-167.

[53] Divers TJ, Whitlock RH. Antimicrobial susceptibility patterns of Clostridium piliforme. Journal of the American Veterinary Medical Association. 193:1135-1138.

[54] Magdesian KG, Divers TJ. Supportive care for foals with hepatic failure. Journal of Equine Veterinary Science. 23:192-198.